Defense World
29 Mar 2026, 08:43 UTC · 26w ago
Verdict
Headline takes no side. We score LMAT +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Seven research firms have assigned LeMaitre Vascular (LMAT) a consensus recommendation of "Moderate Buy".
More positive than 54% of claims this week
Four analysts have rated LMAT as a buy, while three have rated it as a hold.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 46% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company has received a consensus 'Moderate Buy' recommendation from research firms.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−22.5%
Price is moving against the score
$82.59 vs $106.62 close before publication (Mar 27) · not market-adjusted
LMAT chart →
